Capricor Therapeutics, Inc. (CAPR) Research

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering transformative cell and exosome-based therapies to treat and prevent a diverse range of diseases and disorders. Their lead therapeutic, CAP-1002, is an allogeneic cell therapy derived from heart tissue. This candidate has successfully completed its Phase III clinical trial for patients afflicted with late-stage Duchenne muscular dystrophy (DMD). CAP-1002 is simultaneously progressing through Phase II clinical testing to address cytokine storm associated with SARS-CoV-2. Beyond CAP-1002, the company is advancing CAP-2003 through preclinical development, aiming to treat trauma-related injuries and medical conditions. Furthermore, Capricor is developing two vaccine candidates with the potential to prevent COVID-19. Capricor collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, supporting its use in DMD and other indications. The company was established in 2005 and is headquartered in San Diego, California.

Market snapshot

Symbol
CAPR
Price
$28.38
Day change
+1.54%
Market cap
$1.3B
P/E ratio
-14.22x
52-week range
4.3-40.37
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$50.00

Recent news

  • Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

    Capricor Therapeutics Inc. (NASDAQ:CAPR) on Thursday filed a lawsuit against Nippon Shinyaku Co., Ltd. and its U.S. subsidiary NS Pharma, Inc., alleging that flaws in the companies' U.S. distribution agreement for experimental Duchenne muscular dystrophy treatment Deramiocel could limit patient access to the therapy.

Peer companies

  • Achieve Life Sciences, Inc. (ACHV)
  • Allogene Therapeutics, Inc. (ALLO)
  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Cabaletta Bio, Inc. (CABA)
  • Editas Medicine, Inc. (EDIT)
  • Immutep Limited (IMMP)
  • Lexeo Therapeutics, Inc. Common Stock (LXEO)
  • ProQR Therapeutics N.V. (PRQR)

Recent insider activity

  • Maurer Michael T — A-Award (80000 shares) on 2026-05-26
  • Maurer Michael T — trade (0 shares) on 2026-05-25
  • Bergmann Anthony — M-Exempt (3000 shares) on 2026-05-18
  • Bergmann Anthony — M-Exempt (3000 shares) on 2026-05-18
  • Litvack Frank — M-Exempt (3937 shares) on 2026-05-13

Open Capricor Therapeutics, Inc. (CAPR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.